Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women?

CAROLINE C. MARRS, Maged Costantine

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Preeclampsia is a multisystem disorder that affects 3% to 5% of pregnant women and remains a significant source of short-term and long-term maternal and neonatal mortality and morbidity. Many professional societies recommend the use of low-dose aspirin to prevent preeclampsia in high-risk women. Owing to the similarities in pathophysiology between preeclampsia and atherosclerotic cardiovascular disease, and the encouraging data from preclinical and pilot clinical studies, pravastatin has been proposed for preventing preeclampsia. However, before statin administration becomes part of routine clinical practice, a large, well-designed, and adequately powered randomized-controlled trial is needed.

Original languageEnglish (US)
JournalClinical Obstetrics and Gynecology
DOIs
StateAccepted/In press - Nov 30 2016

Fingerprint

Pravastatin
Pre-Eclampsia
Aspirin
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Maternal Mortality
Infant Mortality
Pregnant Women
Cardiovascular Diseases
Randomized Controlled Trials
Morbidity

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women? / MARRS, CAROLINE C.; Costantine, Maged.

In: Clinical Obstetrics and Gynecology, 30.11.2016.

Research output: Contribution to journalArticle

@article{9606aea4f6474411b2f9cb3291712005,
title = "Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women?",
abstract = "Preeclampsia is a multisystem disorder that affects 3{\%} to 5{\%} of pregnant women and remains a significant source of short-term and long-term maternal and neonatal mortality and morbidity. Many professional societies recommend the use of low-dose aspirin to prevent preeclampsia in high-risk women. Owing to the similarities in pathophysiology between preeclampsia and atherosclerotic cardiovascular disease, and the encouraging data from preclinical and pilot clinical studies, pravastatin has been proposed for preventing preeclampsia. However, before statin administration becomes part of routine clinical practice, a large, well-designed, and adequately powered randomized-controlled trial is needed.",
author = "MARRS, {CAROLINE C.} and Maged Costantine",
year = "2016",
month = "11",
day = "30",
doi = "10.1097/GRF.0000000000000248",
language = "English (US)",
journal = "Clinical Obstetrics and Gynecology",
issn = "0009-9201",
publisher = "Lippincott Williams and Wilkins",

}

TY - JOUR

T1 - Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women?

AU - MARRS, CAROLINE C.

AU - Costantine, Maged

PY - 2016/11/30

Y1 - 2016/11/30

N2 - Preeclampsia is a multisystem disorder that affects 3% to 5% of pregnant women and remains a significant source of short-term and long-term maternal and neonatal mortality and morbidity. Many professional societies recommend the use of low-dose aspirin to prevent preeclampsia in high-risk women. Owing to the similarities in pathophysiology between preeclampsia and atherosclerotic cardiovascular disease, and the encouraging data from preclinical and pilot clinical studies, pravastatin has been proposed for preventing preeclampsia. However, before statin administration becomes part of routine clinical practice, a large, well-designed, and adequately powered randomized-controlled trial is needed.

AB - Preeclampsia is a multisystem disorder that affects 3% to 5% of pregnant women and remains a significant source of short-term and long-term maternal and neonatal mortality and morbidity. Many professional societies recommend the use of low-dose aspirin to prevent preeclampsia in high-risk women. Owing to the similarities in pathophysiology between preeclampsia and atherosclerotic cardiovascular disease, and the encouraging data from preclinical and pilot clinical studies, pravastatin has been proposed for preventing preeclampsia. However, before statin administration becomes part of routine clinical practice, a large, well-designed, and adequately powered randomized-controlled trial is needed.

UR - http://www.scopus.com/inward/record.url?scp=85000919277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85000919277&partnerID=8YFLogxK

U2 - 10.1097/GRF.0000000000000248

DO - 10.1097/GRF.0000000000000248

M3 - Article

JO - Clinical Obstetrics and Gynecology

JF - Clinical Obstetrics and Gynecology

SN - 0009-9201

ER -